A vaccine provides controlled exposure to a pathogen, trains and strengthens the immune system to quickly and effectively fight this disease in the future. By mimicking an infection, the vaccine protects us from real pathogens. Over the past decade, vaccine development has received tremendous support from the pharmaceutical industry and governments through successful vaccination programs that have helped eradicate infectious diseases such as chickenpox and polio around the world, saving billions of dollars in healthcare spending.

In its latest publication Regarding the vaccines market, Meticulous Research says the market is estimated at $ 187 billion in 2021, with COVID-19 vaccines contributing $ 137 billion. The COVID-19 vaccine market is expected to mature in the coming years, with most of the world’s population being vaccinated against the coronavirus. The COVID-free vaccine market is projected to reach $ 81 billion by 2028 and grow at a CAGR of 7.2% from 2021 to 2028.

The growth of the global vaccine market is mainly due to the increasing prevalence of diseases, increasing government initiatives traced back to immunization, technological advances in the vaccine industry, the existence of a strong pipeline for vaccines and the emergence of the COVID-19 pandemic. In addition, the increasing epidemic potential, growing focus on therapeutic vaccines, and emerging markets are expected to provide significant growth opportunities for vaccine market players.

To enable efficient analysis, Meticulous Research has analyzed this market by indication (pneumococcal, influenza, Rotavirus, hepatitis and COVID-19), route of administration (intramuscular, subcutaneous and oral), type (inactivated, live attenuated and subunit segmented vaccines), valence (multivalent and monovalent) and geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa).

Geographically, North America had the largest market share, followed by Asia Pacific. Most of North America is largely attributed to increasing government and business efforts to mandate vaccinations in the area and develop new vaccines. In addition, the continued R&D of leading manufacturers to develop new, innovative and more effective vaccines and new facilities in the region, as well as compulsory or compulsory vaccination in the US are the factors responsible for the growth of the region.

Regarding on the disease indication, the COVID-19 vaccine segment is estimated to have the largest share of the total vaccine market. The recent introduction of COVID-19 vaccines in many countries (and a few others in development) coupled with increasing cases of infection / death from the disease has put the accelerated and widespread adoption of the vaccines under public and political pressure > In terms of the antigen used in the preparation, the vaccines market is broadly divided into five main types: live attenuated vaccines, inactivated vaccines, subunit & conjugate vaccines, toxoid vaccines, and combination vaccines. In 2021, the subunit and conjugate vaccines segment will account for the largest share of the global vaccines market, while inactivated vaccines are expected to grow at the highest CAGR due to their properties such as safety, stability and ease of administration to immunocompromised people due to a lack of chances of pathogen reactivation and Introduction of COVID-19 vaccines.

In terms of value, vaccines are divided into monovalent or polyvalent (multivalent). The multivalent vaccines segment is expected to account for the larger share of the global vaccines market in 2021 due to the new launches of multivalent vaccines and increasing investment by key players in R&D multivalent vaccines, as well as technological advances in the production of multivalent vaccines.

The report provides competitive intelligence in terms of financial data, growth strategies, product portfolios and geographic presence on some of the key players in this market including Sanofi (France), Merck & Co., Inc. (USA), GlaxoSmithKline plc (UK). ), Pfizer Inc. (USA), Johnson & Johnson (USA), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (USA) and AstraZeneca PLC (UK).

Media contact Company name: Meticulous Market Research Pvt Ltd Contact person: Khushal Bombe Email: E Send MailTelephone: 1 646-781-8004Address: 1267 Willis St, Ste 200 Redding, California, 96001, USA Country: United StatesWebsite: www.meticulousresearch.com

Cowboys crowd at Texas Stadium. – Billy Bob Bain (CC SA 2.0) The NAACP has a letter to the players’ associations for several professionals …

Oleg Tinkov, owner of Tinkoff Bank and the Tinkoff Cycling Team, paid $ 509 million to the US – Pay tax evasion charges. – Copyright VATICAN MEDIA / AFP HandoutRussian …

A boy works in a cannabis field on the outskirts of Kandahar – Copyright AFP BULENT KILICDaphne ROUSSEAUA Afghanistan’s new Taliban authorities swear …

Prince Andrew has allegations he did Had sex with Virginia Giuffre, vehemently rejected and said he couldn’t remember meeting her – Copyright AFP…

COPYRIGHT © 1998 – 2021 DIGITAL JOURNAL INC.

Digital Journal is not responsible for the content of external sites. Read more about our external linking.

Ref: https://www.digitaljournal.com